Cargando…
Pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation
OBJECTIVES: The purpose of the study was to assess the validity of the hematopoietic cell transplantation‐specific comorbidity index (HCT‐CI) and of pulmonary comorbidity prior to HCT in terms of predicting non‐relapse mortality (NRM) and overall survival (OS). METHODS: In this retrospective single‐...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092052/ https://www.ncbi.nlm.nih.gov/pubmed/36153797 http://dx.doi.org/10.1111/ejh.13869 |
_version_ | 1785023257308561408 |
---|---|
author | Schierbeck, Frederikke Mortensen, Jann Andersen, Niels S. Friis, Lone S. Kornblit, Brian Petersen, Søren L. Schjødt, Ida Sengeløv, Henrik |
author_facet | Schierbeck, Frederikke Mortensen, Jann Andersen, Niels S. Friis, Lone S. Kornblit, Brian Petersen, Søren L. Schjødt, Ida Sengeløv, Henrik |
author_sort | Schierbeck, Frederikke |
collection | PubMed |
description | OBJECTIVES: The purpose of the study was to assess the validity of the hematopoietic cell transplantation‐specific comorbidity index (HCT‐CI) and of pulmonary comorbidity prior to HCT in terms of predicting non‐relapse mortality (NRM) and overall survival (OS). METHODS: In this retrospective single‐center study of 663 consecutive adult recipients of HCT, we stratified patients into groups by pulmonary comorbidity: low‐risk, intermediate‐risk, and high‐risk. The predictive value of this pulmonary comorbidity score (PCS) was compared to HCT‐CI. RESULTS: In univariate analysis, the HCT‐CI and the PCS were associated with OS after transplantation when comparing patients in high‐risk groups with patients in low‐risk groups. Using the PCS, the hazard ratios (HRs) of the 2‐year OS in the entire population and in the myeloablative conditioning (MAC) group were 1.98 (p < .001) and 3.27 (p < .001), respectively, whereas the HRs using the HCT‐CI were 1.83 (p < .001) and 2.57 (p = .002). The 2‐year NRM incidence in the three risk‐groups in the entire population was significant using both indexes. In the MAC group, the 2‐year NRM was significant using the PCS (p = .003), but not using the HCT‐CI (p = .23). CONCLUSIONS: Our study suggest that pulmonary function alone is a strong predictor of 2‐year OS and NRM after HCT. |
format | Online Article Text |
id | pubmed-10092052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100920522023-04-13 Pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation Schierbeck, Frederikke Mortensen, Jann Andersen, Niels S. Friis, Lone S. Kornblit, Brian Petersen, Søren L. Schjødt, Ida Sengeløv, Henrik Eur J Haematol Original Articles OBJECTIVES: The purpose of the study was to assess the validity of the hematopoietic cell transplantation‐specific comorbidity index (HCT‐CI) and of pulmonary comorbidity prior to HCT in terms of predicting non‐relapse mortality (NRM) and overall survival (OS). METHODS: In this retrospective single‐center study of 663 consecutive adult recipients of HCT, we stratified patients into groups by pulmonary comorbidity: low‐risk, intermediate‐risk, and high‐risk. The predictive value of this pulmonary comorbidity score (PCS) was compared to HCT‐CI. RESULTS: In univariate analysis, the HCT‐CI and the PCS were associated with OS after transplantation when comparing patients in high‐risk groups with patients in low‐risk groups. Using the PCS, the hazard ratios (HRs) of the 2‐year OS in the entire population and in the myeloablative conditioning (MAC) group were 1.98 (p < .001) and 3.27 (p < .001), respectively, whereas the HRs using the HCT‐CI were 1.83 (p < .001) and 2.57 (p = .002). The 2‐year NRM incidence in the three risk‐groups in the entire population was significant using both indexes. In the MAC group, the 2‐year NRM was significant using the PCS (p = .003), but not using the HCT‐CI (p = .23). CONCLUSIONS: Our study suggest that pulmonary function alone is a strong predictor of 2‐year OS and NRM after HCT. John Wiley and Sons Inc. 2022-10-21 2023-01 /pmc/articles/PMC10092052/ /pubmed/36153797 http://dx.doi.org/10.1111/ejh.13869 Text en © 2022 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Schierbeck, Frederikke Mortensen, Jann Andersen, Niels S. Friis, Lone S. Kornblit, Brian Petersen, Søren L. Schjødt, Ida Sengeløv, Henrik Pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation |
title | Pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation |
title_full | Pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation |
title_fullStr | Pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation |
title_full_unstemmed | Pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation |
title_short | Pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation |
title_sort | pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092052/ https://www.ncbi.nlm.nih.gov/pubmed/36153797 http://dx.doi.org/10.1111/ejh.13869 |
work_keys_str_mv | AT schierbeckfrederikke pulmonaryfunctionisastrongpredictorof2yearoverallsurvivalandnonrelapsemortalityafterallogenichematopoieticcelltransplantation AT mortensenjann pulmonaryfunctionisastrongpredictorof2yearoverallsurvivalandnonrelapsemortalityafterallogenichematopoieticcelltransplantation AT andersennielss pulmonaryfunctionisastrongpredictorof2yearoverallsurvivalandnonrelapsemortalityafterallogenichematopoieticcelltransplantation AT friislones pulmonaryfunctionisastrongpredictorof2yearoverallsurvivalandnonrelapsemortalityafterallogenichematopoieticcelltransplantation AT kornblitbrian pulmonaryfunctionisastrongpredictorof2yearoverallsurvivalandnonrelapsemortalityafterallogenichematopoieticcelltransplantation AT petersensørenl pulmonaryfunctionisastrongpredictorof2yearoverallsurvivalandnonrelapsemortalityafterallogenichematopoieticcelltransplantation AT schjødtida pulmonaryfunctionisastrongpredictorof2yearoverallsurvivalandnonrelapsemortalityafterallogenichematopoieticcelltransplantation AT sengeløvhenrik pulmonaryfunctionisastrongpredictorof2yearoverallsurvivalandnonrelapsemortalityafterallogenichematopoieticcelltransplantation |